IMMUNOCELLULAR THERAPEUTICS (IMUC) Stock Overview
USA - NYSEARCA:IMUC - US4525362046
IMUC Key Statistics, Chart & Performance
The current stock price of IMUC is 0.053 null. In the past month the price decreased by -74.76%. In the past year, price decreased by -86.75%.
IMUC Latest News, Press Relases and Analysis
About IMUC
Company Profile
ImmunoCellular Therapeutics, Ltd. operates as a development stage company with primary focus on the development and commercialization of new therapeutics to fight cancer using the immune system. Its product candidate portfolio includes cellular immunotherapies targeting cancer and cancer stem cell antigens, peptide based immunotherapies targeting cancer stem cells, and monoclonal antibodies to diagnose and treat several different cancers. ImmunoCellular Therapeutics, Ltd. is based in California, USA.
Company Info
IMMUNOCELLULAR THERAPEUTICS
23622 CALABASAS ROAD SUITE 300
CALABASAS CA 91302
CEO: Anthony Gringeri
Phone: 818-264-2300
IMMUNOCELLULAR THERAPEUTICS / IMUC FAQ
What does IMUC do?
ImmunoCellular Therapeutics, Ltd. operates as a development stage company with primary focus on the development and commercialization of new therapeutics to fight cancer using the immune system. Its product candidate portfolio includes cellular immunotherapies targeting cancer and cancer stem cell antigens, peptide based immunotherapies targeting cancer stem cells, and monoclonal antibodies to diagnose and treat several different cancers. ImmunoCellular Therapeutics, Ltd. is based in California, USA.
What is the stock price of IMMUNOCELLULAR THERAPEUTICS today?
The current stock price of IMUC is 0.053 null. The price decreased by -75.91% in the last trading session.
What is the dividend status of IMMUNOCELLULAR THERAPEUTICS?
IMUC does not pay a dividend.
What is the ChartMill technical and fundamental rating of IMUC stock?
IMUC has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the short interest for IMUC stock?
The outstanding short interest for IMMUNOCELLULAR THERAPEUTICS (IMUC) is 0% of its float.
IMUC Technical Analysis
IMUC Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to IMUC. While IMUC seems to be doing ok healthwise, there are quite some concerns on its profitability.
IMUC Financial Highlights
Over the last trailing twelve months IMUC reported a non-GAAP Earnings per Share(EPS) of -1.4500000000000002. The EPS increased by 86.7% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -159.47% | ||
| ROE | -178.18% | ||
| Debt/Equity | 0 |